Telix Strengthens Board with Additional Director Appointments
Telix today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026, as part of Board expansion and succession planning
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
Telix Appoints David Gill as Non-Executive Director
Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill is expected to be appointed Chair, succeeding Dr. Mark Nelson who will remain on the Board as a NED.
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Telix today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Telix today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix today announces its financial results for the year ended December 31, 2025.
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Telix today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate.
Telix Full Year Results 2025 Investor Webcast Notification
Telix advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST).
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Telix provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025).
Presentation to J.P. Morgan Healthcare Conference
Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).